Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$17,500.00

The impact of pathogenic DNMT3A on neurodevelopment

EF 2022-23

Résumé
Establishment of DNA methylation by DNMT3A (DNA methyltransferase 3A) plays an essential role in regulating proper stem cell fate specification, especially in neural stem cells during brain development. In 2014, human heterozygous germline mutations in functional domains of DNMT3A were associated to a rare congenital overgrowth disorder called Tatton-Brown-Rahman Syndrome (TBRS). TBRS patients are particularly affected with neurodevelopmental disorders, with individuals showing varying levels of severity. However, due to the inherent lack of appropriate TBRS patient sample availability and animal models not recapitulating disease phenotypes, we do not know how functional DNMT3A mutations induce impairments in molecular (e.g., epigenetic, transcriptomic) and cellular (e.g., brain lineage specification) processes at the origin of the neurodevelopmental problems observed in TBRS patients. For my project, I will use the McGraw lab new TBRS (Dnmt3a+/R684H) mouse model to define how this disease-causing DNMT3A mutation alters developmental trajectories. I hypothesize that pathogenic Dnmt3a+/R684H variant leads to abnormal brain development and function linked to DNA methylation programming errors. My 3 focused research aims are: Aim 1. Determine how the Dnmt3a+/R684H variant alters the development and fate of brain cells. Aim 2. Define if the Dnmt3a+/R684H variant phenocopies aspects of human TBRS. Aim 3. Define how Dnmt3a+/R684H dysregulates the epigenetic and transcriptomic programs of brain cells. Impact. Since TBRS patients have similar congenital defects, this novel mouse model will provide much needed information on the dysregulation of molecular and developmental pathways associated with disease pathogenesis and allow for future therapeutic screening.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486179
Name
Robb Michelle
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The impact of pathogenic DNMT3A on neurodevelopment
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Behavior; Brain Development; Confocal Imaging; Dna Methylation; Dna Methyltransferase 3a (Dnmt3a); Epigenetics; Mouse Model; Neurodevelopment; Tatton-Brown-Rahman Syndrome (Tbrs); Transcriptomics
Abstract
Establishment of DNA methylation by DNMT3A (DNA methyltransferase 3A) plays an essential role in regulating proper stem cell fate specification, especially in neural stem cells during brain development. In 2014, human heterozygous germline mutations in functional domains of DNMT3A were associated to a rare congenital overgrowth disorder called Tatton-Brown-Rahman Syndrome (TBRS). TBRS patients are particularly affected with neurodevelopmental disorders, with individuals showing varying levels of severity. However, due to the inherent lack of appropriate TBRS patient sample availability and animal models not recapitulating disease phenotypes, we do not know how functional DNMT3A mutations induce impairments in molecular (e.g., epigenetic, transcriptomic) and cellular (e.g., brain lineage specification) processes at the origin of the neurodevelopmental problems observed in TBRS patients. For my project, I will use the McGraw lab new TBRS (Dnmt3a+/R684H) mouse model to define how this disease-causing DNMT3A mutation alters developmental trajectories. I hypothesize that pathogenic Dnmt3a+/R684H variant leads to abnormal brain development and function linked to DNA methylation programming errors. My 3 focused research aims are: Aim 1. Determine how the Dnmt3a+/R684H variant alters the development and fate of brain cells. Aim 2. Define if the Dnmt3a+/R684H variant phenocopies aspects of human TBRS. Aim 3. Define how Dnmt3a+/R684H dysregulates the epigenetic and transcriptomic programs of brain cells. Impact. Since TBRS patients have similar congenital defects, this novel mouse model will provide much needed information on the dysregulation of molecular and developmental pathways associated with disease pathogenesis and allow for future therapeutic screening.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Robb, Michelle
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~